We are very pleased to announce that Dr Ana Slipicevic has been appointed as acting CEO of one-carbon therapeutics AB. Ana is joining us from Oncopeptides AB where she has been translational research director and leading a team developing and implementing translational research strategies in the early and late-stage clinical trial pipeline. Dr Ana Slipicevic has previously been leading a research team at Oslo University working on DDR strategies to target cancer.
She will be a great asset to the company!
One-carbon Therapeutics Announces Strategic Collaboration with Tempus to Advance Molecular Insights and Enable Precision Oncology Development of TH9619
Solna, Sweden, March 17h, 2026. One-carbon Therapeutics, a clinical-stage oncology
